Oct. 8 (Bloomberg) - Boehringer Ingelheim GmbH abandoned development of its female desire drug flibanserin after U.S. regulators said the pill wasn’t proven to be safe and effective.
Boehringer is still convinced flibanserin would have helped women, Chief Executive Officer Andreas Barner said in an e- mailed statement today. “The decision was not made lightly, considering the advanced stage of development,” he said.
via bloomberg.com
